Vena cava superior syndrome. Analisis of interventional and medical treatment options

We present a clinical case of a 72-year-old man with a history of hypertension and SARS-CoV-2 infection, urgently hospitalized in the intensive care unit due to dyspnea at rest, blushes and swelling of the neck and face, headache, and syncope. Echocardiography was performed and revealed preserved ejection fraction of left and right ventricle (EF – 57%, TAPSE – 21 mm), without hemodynamically significant valve lesions and normal ECG. On the next day of hospitalization, we performed a computer tomography (CT) scan of the lungs and it showed a tumor in right lung, compressing vena cava superior. Venography was performed and revealed subtotal thrombosis of vena cava superior and stenting with Wallstent 16/60 mm was performed. Six hours after the intervention a clinical improvement was achieved – reducing of the swelling and relieving of the symptoms.

Well Differentiated B3 Thymoma complicated with Vena Cava Superior Syndrome undergo Debulking and Chemotherapy

Background: Thymoma is a rare neoplasm. This incident is comparable to 390 new cases reported per year. Genetic factors are believed to be one of the factors of B3 thymoma and thymus carcinoma. Multimodality of thymoma therapy (surgery, radiation and chemotherapy) gives better results. Case Report: Mr A, 29 years old, with initial diagnosis of stage IV thymoma (according to Masaoka) with SVKS then undergo debulking, followed by chemotherapy with a regimen of Cisplatin + Vincristin, Cyclophospamid, Doxorubicin, Prednison every 21 days as much as 6 times. Subjective responses indicated by reduced complaints of chest pain and loss of swelling of the right arm. Semisubjective response indicated by increase of body weight. Objective response is progressive, so can be continued with second line chemotherapy or radiotherapy. Conclusion: The prognosis of patient with well differentiated thymic carcinoma stadium iv (thymoma b3) complicated with vena cava superior syndrome was poor because of the objective response of the chemotherapy was progressive, and the relapse case was higher.

Lung Cancer Patients’ Profile in Dr Soetomo General Hospital Surabaya 2016 - 2017: Newest Report

A B S T R A C TMethods: This research was a descriptive observational study. The samples were 240 patients of lung cancer in Poly Oncology Dr. Soetomo General Hospital Surabaya 2016-2017. Sampling technique was non-random sampling (consecutive sampling). The variables were: age, sex, smoking habits, type of lung cancer, type of mutation, stage, symptoms, Vena Cava Superior syndrome, and therapy. The data analyzed were analyzed descriptively.Results: Patients mostly at age 51-55 and 56-60 years old (18% each). Ratio men and women are 1,7:1. In all type of lung cancer, men are dominant than women and mostly patients is active smoker. Ephidermal Growth Factor Receptor (EGFR) mutation found in adenosquamous (75%) and adenocarcinoma (65%). Most patients diagnosed at advance stage. Most symptoms are cough (70.4%), dyspnoea (50%), and chest pain (49.2%). Vena Cava Superior Syndrome (VCSS) found in adenocarcinoma (75%) and squamous cell carcinoma (25%). In adenocarcinoma and adenosquamous, patients commonly got targeted therapy.Conclusion: Lung cancer patients: 1) Men tend to be exposed to younger than women, 2) ratio men and women is 1.7:1 and most type in lung cancer is adenocarcinoma 3) mostly patients is active smoker, 4) EGFR mutation tent to be in women with adenocarcinoma, 5) most stage is stage IV, 6) most symptoms is cough, 7) Vena Cava Superior Syndrome is in adenocarcinoma (75%) and carcinoma cell squamous (25%), 8) patients’ therapy mostly with targeted therapy followed by chemotherapy.